Velcade (also known as PS-341 or Bortezomib) is a highly selective and reversible inhibitor
of the 26S proteasome and is approved for the treatment of patients with advanced multiple …

Inhibition of the proteasome has emerged as a clinically effective anticancer therapeutic
approach in recent years. Bortezomib (Velcade®) showed extremely high potency against a …

The 26S proteasome is a large multi-subunit protein complex found in the cytoplasm and
nucleus of mammalian cells which plays a critical role in intracellular proteolysis. It has been …

Proteasome inhibition is associated with substantial antitumor effects in preclinical models of
multiple myeloma (MM) as well as in patients. However, results of recent clinical trials to …

Purpose: The success of bortezomib therapy for treatment of multiple myeloma (MM) led to
the development of structurally and pharmacologically distinct novel proteasome inhibitors …

The proteasome inhibitor bortezomib (PS341) inhibits the function of the 26S proteasome
and has been extensively investigated in the clinical setting of hematologic malignancies …

Objectives: The ubiquitin–proteasome system emerged as a new therapeutic target in
cancer treatment. The purpose of this study was to elucidate the effects of the novel …

The proteasome was validated as an oncology target following the clinical success of
VELCADE (bortezomib) for injection for the treatment of multiple myeloma and recurring …

Protein degradation by proteasome is essential to the regulation of important cellular
functions including cell cycle progression, proliferation, differentiation and apoptosis …

Purpose In this study, we investigated the effects of cell-permeable proteasome inhibitors
MG-132, MG-262, PSI, and lactacystin on multiple myeloma cell lines OPM-2, U266, RPMI …